Sound View Wealth Advisors Group LLC Sells 42,381 Shares of Bristol Myers Squibb Company $BMY

Sound View Wealth Advisors Group LLC lessened its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 14.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 260,569 shares of the biopharmaceutical company’s stock after selling 42,381 shares during the period. Bristol Myers Squibb accounts for about 0.9% of Sound View Wealth Advisors Group LLC’s investment portfolio, making the stock its 28th biggest holding. Sound View Wealth Advisors Group LLC’s holdings in Bristol Myers Squibb were worth $14,055,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb in the second quarter worth approximately $25,000. Harbor Capital Advisors Inc. raised its position in Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 313 shares in the last quarter. KERR FINANCIAL PLANNING Corp purchased a new stake in shares of Bristol Myers Squibb in the 3rd quarter worth $35,000. JPL Wealth Management LLC bought a new position in shares of Bristol Myers Squibb during the 3rd quarter worth $36,000. Finally, Total Investment Management Inc. bought a new position in shares of Bristol Myers Squibb during the 2nd quarter worth $38,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: U.S. and EMA approvals expanded Opdivo’s use into frontline Stage III/IV classical Hodgkin’s lymphoma for patients 12+, strengthening BMY’s oncology franchise and near‑term revenue potential. Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo US FDA approves Bristol Myers Squibb’s cancer drug for Hodgkin’s lymphoma
• Positive Sentiment: Sotyktu (BMY) received a label expansion into psoriatic arthritis, broadening BMY’s immunology franchise and helping offset pressure from legacy oncology and cardiovascular patent cliffs. Will the Recent Label Expansion of BMY’s Sotyktu Boost Its Prospects?
• Positive Sentiment: BMY advanced its protein‑degradation program: first‑in‑human dosing of BMS‑986506 for clear cell renal cell carcinoma triggered a $10M milestone to Evotec, signaling pipeline progress and potential long‑term upside if early data read out well. Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration
• Neutral Sentiment: HSBC nudged its price target to $60, a modest analyst upgrade that signals some confidence but is unlikely to drive large near‑term moves on its own. HSBC Boosts Bristol Myers Squibb (NYSE:BMY) Price Target to $60.00
• Neutral Sentiment: BMY scheduled Q1 2026 results for April 30 — a near‑term event that could reprice the stock depending on revenue and EPS versus guidance/expectations. Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
• Neutral Sentiment: Coverage pieces (Schaeffer, Zacks) have highlighted BMY as a recommended pick or trending ticker, which can lift interest but may already be priced in. Top Stock Picks of 2026: Bristol-Myers Squibb Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
• Negative Sentiment: Technical weakness flagged by a potential “death cross” (50‑day moving average crossing below 200‑day) can prompt selling by trend‑followers and contributed to the down‑pressure. These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity

Wall Street Analysts Forecast Growth

BMY has been the subject of several recent research reports. Guggenheim restated a “buy” rating and issued a $72.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. UBS Group reiterated a “buy” rating and set a $70.00 target price on shares of Bristol Myers Squibb in a report on Friday, March 6th. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their target price for the company from $52.00 to $61.00 in a research report on Monday, December 15th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Finally, Scotiabank reiterated a “sector perform” rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Nine equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $61.41.

Bristol Myers Squibb Stock Down 1.2%

NYSE:BMY opened at $57.42 on Friday. The company’s 50-day simple moving average is $58.60 and its 200-day simple moving average is $51.84. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The stock has a market capitalization of $116.93 billion, a P/E ratio of 16.64, a P/E/G ratio of 0.16 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter last year, the firm earned $1.67 EPS. The company’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.